Neutropenia after rituximab treatment: new insights on a late complication

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current opinion in hematology

• Publication date

  2012-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MOH.0b013e32834da987PMID 22080846
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Colony-Stimulating Factors and Cancer

  2013cited by this paper
• Homozygous FCGR3A‐158V alleles predispose to late onset neutropenia after CHOP‐R for diffuse large B‐cell lymphoma

  2011cited by this paper
• Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non‐Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study

  2011cited by this paper
• Neutropenia associated with rituximab therapy

  2011cited by this paper
• Does rituximab increase the incidence of infectious complications? A narrative review.

  2011cited by this paper
• Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.

  2011cited by this paper
• Is Rituximab‐induced Late‐onset Neutropenia a good prognostic indicator in lymphoproliferatve disorders?

  2011cited by this paper
• New drugs for aggressive B-cell and T-cell lymphomas.

  2010cited by this paper
• Late-Onset Neutropenia After Rituximab Treatment: Case Series and Comprehensive Review of the Literature

  2010influential reference
• Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

  2010cited by this paper
• Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis

  2010cited by this paper
• Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events.

  2010influential reference
• B‐cell targeted therapies in human autoimmune diseases: an updated perspective

  2010cited by this paper
• The colony-stimulating factors and cancer

  2010cited by this paper
• Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.

  2010cited by this paper
• Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.

  2010influential reference
• Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.

  2010cited by this paper
• Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab.

  2009influential reference
• Late‐onset neutropenia following RCHOP chemotherapy in diffuse large B‐cell lymphoma

  2009cited by this paper
• The late adverse events of rituximab therapy – rare but there!

  2009cited by this paper
• A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

  2009cited by this paper
• Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia

  2008cited by this paper
• Idiosyncratic drug-induced agranulocytosis or acute neutropenia

  2008cited by this paper
• Late-onset neutropenia following viral bone marrow depression after rituximab therapy

  2008influential reference
• Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.

  2008cited by this paper
• Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis

  2008cited by this paper
• Off‐label uses of rituximab in dermatology

  2007cited by this paper
• Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.

  2007cited by this paper
• Rituximab therapy in malignant lymphoma

  2007cited by this paper
• Late‐onset neutropenia following rituximab treatment in patients with autoimmune diseases

  2007cited by this paper
• Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs

  2007cited by this paper
• Rituximab for the treatment of autoimmune cytopenias

  2007cited by this paper
• Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma

  2006cited by this paper
• A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study.

  2006cited by this paper
• Rituximab: a promising therapy in systemic lupus erythematosus.

  2006cited by this paper
• Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment.

  2006influential reference
• Late-Onset Neutropenia in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma

  2006cited by this paper
• Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments

  2006cited by this paper
• Tolerability and safety of rituximab (MabThera).

  2005cited by this paper
• B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.

  2005cited by this paper
• From the bench to the bedside: ways to improve rituximab efficacy.

  2004cited by this paper
• Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

  2004cited by this paper
• Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma

  2004influential reference
• High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.

  2004influential reference
• Rituximab-associated immune myelopathy.

  2003cited by this paper
• Delayed‐onset neutropenia associated with rituximab therapy

  2003cited by this paper
• Neutropenia in patients treated with rituximab.

  2003cited by this paper
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases.

  2002cited by this paper
• Colony-Stimulating Factors for the Management of Neutropenia in Cancer Patients

  2002cited by this paper
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

  2002cited by this paper
• Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.

  2000cited by this paper
• Chronic neutropenia mediated by fas ligand.

  2000cited by this paper
• CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndromes.

  2000cited by this paper
• Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.

  2000cited by this paper
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

  1998cited by this paper

• Neutropenia Associated With B Cell–Depleting Therapies in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder

  2025cites this paper
• Management of refractory autoimmune hepatitis with rituximab: a case series

  2025cites this paper
• Ocrelizumab-induced neutropenia in people with multiple sclerosis: a single-centre study.

  2025cites this paper
• Recurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis.

  2024cites this paper
• Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

  2023cites this paper
• Cryobiology and Cryomedicine Techniques’ Boosting in Wartime

  2023cites this paper
• Infections in patients with chronic lymphocytic leukemia

  2023cites this paper
• An update on the incidence, risk factors and mechanisms of rituximab-associated neutropenia

  2022cites this paper
• Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma

  2022cites this paper
• The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas

  2021cites this paper
• Late-onset neutropenia after anti-CD20 therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG antibody-associated disease: A prospective study.

  2021cites this paper
• Late onset neutropenia after rituximab and obinutuzumab treatment – characteristics of a class-effect toxicity

  2021influential citation
• Long-Term Outcome of ABO-Incompatible Kidney Transplantation in Patients Treated With Low-Dose Rituximab Regimen.

  2020cites this paper
• Partial response in hairy cell leukemia with vemurafenib despite early discontinuation due to agranulocytosis.

  2020cites this paper
• State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies

  2019cites this paper
• Cold agglutinin disease and its implications for dental treatment.

  2019cites this paper
• Biotherapies-induced neutropenia in autoimmune and auto-inflammatory disorders and other orphan diseases

  2019cites this paper
• Risk factors for post‐transplant lymphoproliferative disorder after Thymoglobulin‐conditioned hematopoietic cell transplantation

  2018cites this paper
• A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia

  2018cites this paper
• Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL

  2018cites this paper
• Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder

  2018cites this paper
• Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation

  2018cites this paper
• Immunotherapy in Waldenstrom’s Macroglobulinemia

  2017cites this paper
• Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab

  2017cites this paper
• Rituximab for immunologic renal disease: What the nephrologist needs to know.

  2017cites this paper
• Late-onset neutropenia after rituximab in ANCA-associated vasculitis

  2016cites this paper
• Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.

  2016cites this paper
• Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects

  2016cites this paper
• Suppression of normal immune responses after treatment with rituximab

  2016cites this paper
• Erratum to: Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects

  2016cites this paper
• Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis

  2015cites this paper
• Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature.

  2015cites this paper
• Erfolgreiche Behandlung eines therapierefraktären Guillain-Barré-Syndroms mit Alemtuzumab bei einem Patienten mit chronischer lymphatischer Leukämie

  2015cites this paper
• Biologics in dermatology: adverse effects

  2015cites this paper
• Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma

  2015cites this paper
• B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment

  2015cites this paper
• Autoimmune neutropenia.

  2014cites this paper
• Cytotoxic T cell-mediated gastritis after rituximab treatment for gastric malt lymphoma

  2014cites this paper
• The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience

  2014cites this paper
• Monoclonal Antibody Therapy and Renal Transplantation: Focus on Adverse Effects

  2014cites this paper
• Rituximab Treatment for Relapsing Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Systematic Review

  2014cites this paper
• Successful Treatment of Refractory Guillain-Barré Syndrome with Alemtuzumab in a Patient with Chronic Lymphocytic Leukemia

  2014cites this paper
• Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma

  2014cites this paper
• Sirolimus as Rescue Therapy in Pediatric Autoimmune Hepatitis

  2014cites this paper
• Successful Treatment With Rituximab of an Epstein-Barr Virus–Associated Leiomyosarcoma Occurring After Liver Transplantation

  2014cites this paper
• Fcγ Receptors as Therapeutic Targets

  2014cites this paper
• Low-dose rituximab in the treatment of acquired haemophilia

  2014cites this paper
• Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica.

  2014influential citation
• Current and future therapeutic approach for Waldenström's macroglobulinemia.

  2014cites this paper
• Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.

  2014cites this paper
• Review article: autoimmune hepatitis – current management and challenges

  2013cites this paper
• Preliminary analysis of mortality associated with rituximab use in autoimmune diseases

  2013cites this paper
• Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab

  2013cites this paper
• Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease

  2013cites this paper
• Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation--single-center study.

  2013cites this paper
• Multiple Cycles of Rituximab Therapy in Chronic Refractory Immune Thrombocytopenia: A Case Report With a 10-Year Follow-up

  2013cites this paper
• Clonal lymphoproliferation of T cell large granular lymphocytes with pleomorphic nuclei following mantle cell lymphoma

  2013cites this paper
• Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review

  2013cites this paper
• Treatment of Paraneoplastic Cerebellar Degeneration

  2013cites this paper
• article : autoimmune hepatitis – current management and challenges

  2013cites this paper
• Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

  2012cites this paper
• Evolutionary karyotypic theory of cancer versus conventional cancer gene mutation theory

  2012cites this paper
• Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation

  2012cites this paper
• Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs

  2012cites this paper
• Cancer Management and Research Dovepress

  year unknowncites this paper